The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK

References

• ChapmanKRManninoDMSorianoJBEpidemiology and costs of chronic obstructive pulmonary diseaseEur Respir J200627118820716387952
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung DiseaseGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary diseaseGlobal Initiative for Chronic Obstructive Lung Disease2015 Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2015.pdfAccessed July 2, 2015
   Google Scholar
• Global Initiative for Chronic Obstructive Lung DiseaseGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary diseaseGlobal Initiative for Chronic Obstructive Lung Disease2013 Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdfAccessed July 2, 2015
   Google Scholar
• National Institute for Health and Care ExcellenceChronic obstructive pulmonary disease: Management of chronic obstructive pulmonary disease in adults in primary and secondary careLondonNational Institute for Health and Care Excellence2004 Available from: https://www.nice.org.uk/guidance/cg101/evidence/cg101-chronic-obstructive-pulmonary-disease-update-full-guideline2Accessed July 2, 2015
   Google Scholar
• AscheCVLeaderSPlauschinatCAdherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroidsInt J Chron Obstruct Pulmon Dis2012720120922500120
   PubMed Web of Science ®Google Scholar
• FitchKIwasakiKPyensonBPlauschinatCZhangJVariation in adherence with Global Initiative for Chronic Obstructive Lung Disease (GOLD) drug therapy guidelines: a retrospective actuarial claims data analysisCurr Med Res Opin20112771425142921599554
   PubMed Web of Science ®Google Scholar
• MasoompourSMMohammadiAMahdaviazadHAdherence to the Global Initiative for Chronic Obstructive Lung Disease guidelines for management of COPD: a hospital-base studyClin Respir J Epub20141013
   Web of Science ®Google Scholar
• MiravitllesMSicrasACrespoCCosts of chronic obstructive pulmonary disease in relation to compliance with guidelines: a study in the primary care settingTher Adv Respir Dis20137313915023653458
   PubMed Web of Science ®Google Scholar
• Canadian Agency for Drugs and Technologies in Health (CADTH)Triple Therapy for Moderate-to-Severe Chronic Obstructive Pulmonary DiseaseCADTH Technol Overv201014e012922977419
   PubMedGoogle Scholar
• GaebelKMcIvorRAXieFTriple therapy for the management of COPD: a reviewCOPD20118320624321513437
   PubMedGoogle Scholar
• KarnerCCatesCJThe effect of adding inhaled corticosteroids to tiotropium and long-acting beta(2)-agonists for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20119CD00903921901729
   PubMed Web of Science ®Google Scholar
• JochmannANeubauerFMiedingerDSchafrothSTammMLeuppiJDGeneral practitioner’s adherence to the COPD GOLD guidelines: baseline data of the Swiss COPD Cohort StudySwiss Med Wkly Epub2010421
   Web of Science ®Google Scholar
• SuissaSBarnesPJInhaled corticosteroids in COPD: the case againstEur Respir J2009341131619567599
   PubMed Web of Science ®Google Scholar
• CorradoARossiAHow far is real life from COPD therapy guidelines? An Italian observational studyRespir Med2012106798999722483189
   PubMed Web of Science ®Google Scholar
• de Miguel-DíezJCarrasco-GarridoPRejas-GutierrezJInappropriate overuse of inhaled corticosteroids for COPD patients: impact on health costs and health statusLung2011189319920621499887
   PubMed Web of Science ®Google Scholar
• FranssenFMSpruitMAWoutersEFDeterminants of polypharmacy and compliance with GOLD guidelines in patients with chronic obstructive pulmonary diseaseInt J Chron Obstruct Pulmon Dis2011649350122069360
   PubMed Web of Science ®Google Scholar
• WongGWMiravitllesMChisholmAKrishnanJARespiratory guidelines – which real world?Ann Am Thorac Soc201411Suppl 2S85S9124559026
   PubMedGoogle Scholar
• CalverleyPPauwelsRVestboJCombined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trialLancet2003361935644945612583942
   PubMed Web of Science ®Google Scholar
• JonesPWWillitsLRBurgePSCalverleyPMInhaled Steroids in Obstructive Lung Disease in Europe study investigatorsDisease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbationsEur Respir J2003211687312570111
   PubMed Web of Science ®Google Scholar
• MahlerDAWirePHorstmanDEffectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary diseaseAm J Respir Crit Care Med200216681084109112379552
   PubMed Web of Science ®Google Scholar
• RossiAvan der MolenTdel OlmoRINSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPDEur Respir J20144461548155625359348
   PubMed Web of Science ®Google Scholar
• CummingRGMitchellPLeederSRUse of inhaled corticosteroids and the risk of cataractsN Engl J Med199733718149203425
   PubMed Web of Science ®Google Scholar
• KimJHParkJSKimKHJeongHCKimEKLeeJHInhaled corticosteroid is associated with an increased risk of TB in patients with COPDChest201314341018102423079688
   PubMed Web of Science ®Google Scholar
• SuissaSKezouhAErnstPInhaled corticosteroids and the risks of diabetes onset and progressionAm J Med2010123111001100620870201
   PubMed Web of Science ®Google Scholar
• WeatherallMJamesKClayJDose-response relationship for risk of non-vertebral fracture with inhaled corticosteroidsClin Exp Allergy20083891451145818537983
   PubMed Web of Science ®Google Scholar
• DiSantostefanoRLSampsonTLeHVHindsDDavisKJBakerlyNDRisk of pneumonia with inhaled corticosteroid versus long-acting bronchodilator regimens in chronic obstructive pulmonary disease: a new-user cohort studyPloS One201495e9714924878543
   PubMed Web of Science ®Google Scholar
• ErnstPGonzalezAVBrassardPSuissaSInhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumoniaAm J Respir Crit Care Med2007176216216617400730
   PubMed Web of Science ®Google Scholar
• SuissaSPatenaudeVLapiFErnstPInhaled corticosteroids in COPD and the risk of serious pneumoniaThorax201368111029103624130228
   PubMed Web of Science ®Google Scholar
• KraemerMEllisABaldwinMJansenJPCapkun-NiggliGCopeSPRS5 dual bronchodilation with indacaterol and tiotropium in combination versus triple therapy, fixed-dose combinations, and monotherapy in COPD – a network meta-analysis of FEV1Value in Health157A560
   Web of Science ®Google Scholar
• MagnussenHDisseBRodriguez-RoisinRWithdrawal of inhaled glucocorticoids and exacerbations of COPDN Engl J Med2014371141285129425196117
   PubMed Web of Science ®Google Scholar
• VogelmeierCFBatemanEDPallanteJEfficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group studyLancet Respir Med201311516024321804
   PubMed Web of Science ®Google Scholar
• HarriesTHSeedPTJonesSSchofieldPWhitePChronic obstructive pulmonary disease hospital admissions and drugs – unexpected positive associations: a retrospective general practice cohort studyNPJ Prim Care Respir Med2014241400624842126
   PubMed Web of Science ®Google Scholar
• Optimum Patient Care Research Database (OPCRD) [webpage on the Internet]Cambridge: Optimum Patient Care2014 Available from: http://www.optimumpatientcare.org/Html_Docs/OPCRD.htmlAccessed July 2, 2015
   Google Scholar
• YohannesAMConnollyMJHananiaNATen years of tiotropium: clinical impact and patient perspectivesInt J Chron Obstruct Pulmon Dis2013811712523515335
   PubMed Web of Science ®Google Scholar
• 2014/15 General Medical Services (GMS)Contract Quality and Outcomes Framework (QOF) [webpage on the Internet]LondonBritish Medical Association2014 Available from: http://bma.org.uk/practical-support-at-work/contracts/independent-contractors/qof-guidanceAccessed July 2, 2015
   Google Scholar
• MiyazakiMNakamuraHTakahashiSThe reasons for triple therapy in stable COPD patients in Japanese clinical practiceInt J Chron Obstruct Pulmon Dis2015101053105926082629
   PubMed Web of Science ®Google Scholar
• BurgelPRDesléeGJebrakGReal-life use of inhaled corticosteroids in COPD patients versus the GOLD proposals: a paradigm shift in GOLD 2011?Eur Respir J20144341201120324176996
   PubMed Web of Science ®Google Scholar
• PapalaMKerenidiNGourgoulianisKIEveryday clinical practice and its relationship to 2010 and 2011 GOLD guideline recommendations for the management of COPDPrim Care Respir J201322336236423989678
   PubMedGoogle Scholar
• SafkaKMcIvorLMcIvorAP252 Gold Category And Optimal Management: A Canadian PerspectiveThorax201469A187A188
   Web of Science ®Google Scholar
• CalverleyPMWhat to use INSTEAD of inhaled corticosteroids in COPD?Eur Respir J20144461391139325435522
   PubMed Web of Science ®Google Scholar
• RossiAGuerrieroMCorradoAOPTIMO/AIPO Study GroupWithdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO)Respir Med20141577
   Google Scholar
• BrusselleGGBrackeKLahousseLTargeted therapy with inhaled corticosteroids in COPD according to blood eosinophil countsLancet Respir Med20153641641725892351
   PubMed Web of Science ®Google Scholar
• PascoeSLocantoreNDransfieldMTBarnesNCPavordIDBlood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trialsLancet Respir Med20153643544225878028
   PubMed Web of Science ®Google Scholar
• LangePMarottJLVestboJPrediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general populationAm J Respir Crit Care Med20121861097598122997207
   PubMed Web of Science ®Google Scholar
• BrusselleGWhy doesn’t reducing exacerbations decrease COPD mortality?Lancet Respir Med20142968168325209987
   PubMed Web of Science ®Google Scholar
• PriceDYawnBBrusselleGRossiARisk-to-benefit ratio of inhaled corticosteroids in patients with COPDPrim Care Respir J20132219210023135217
   PubMedGoogle Scholar
• WhitePThorntonHPinnockHGeorgopoulouSBoothHPOvertreatment of COPD with inhaled corticosteroids – implications for safety and costs: cross-sectional observational studyPloS One2013810e7522124194824
   PubMed Web of Science ®Google Scholar
• SinDDManSFSteroids in COPD: still up in the air?Eur Respir J201035594995120436169
   PubMed Web of Science ®Google Scholar
• HurstJRVestboJAnzuetoASusceptibility to exacerbation in chronic obstructive pulmonary diseaseN Engl J Med2010363121128113820843247
   PubMed Web of Science ®Google Scholar